- Home
- YYGH vs ALXO Comparison
YYGH vs ALXO Comparison
Compare YYGH & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YYGH
- ALXO
- Stock Information
- Founded
- YYGH 2010
- ALXO 2015
- Country
- YYGH Singapore
- ALXO United States
- Employees
- YYGH N/A
- ALXO N/A
- Industry
- YYGH
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- YYGH
- ALXO Health Care
- Exchange
- YYGH NYSE
- ALXO Nasdaq
- Market Cap
- YYGH 68.0M
- ALXO 76.5M
- IPO Year
- YYGH 2024
- ALXO 2020
- Fundamental
- Price
- YYGH $1.98
- ALXO $2.00
- Analyst Decision
- YYGH
- ALXO Strong Buy
- Analyst Count
- YYGH 0
- ALXO 5
- Target Price
- YYGH N/A
- ALXO $13.25
- AVG Volume (30 Days)
- YYGH 32.1K
- ALXO 1.1M
- Earning Date
- YYGH 02-15-2025
- ALXO 11-07-2024
- Dividend Yield
- YYGH N/A
- ALXO N/A
- EPS Growth
- YYGH 527.44
- ALXO N/A
- EPS
- YYGH 0.04
- ALXO N/A
- Revenue
- YYGH $37,372,731.00
- ALXO N/A
- Revenue This Year
- YYGH N/A
- ALXO N/A
- Revenue Next Year
- YYGH N/A
- ALXO N/A
- P/E Ratio
- YYGH $48.51
- ALXO N/A
- Revenue Growth
- YYGH 55.18
- ALXO N/A
- 52 Week Low
- YYGH $0.72
- ALXO $1.19
- 52 Week High
- YYGH $4.70
- ALXO $17.83
- Technical
- Relative Strength Index (RSI)
- YYGH N/A
- ALXO 60.32
- Support Level
- YYGH N/A
- ALXO $1.40
- Resistance Level
- YYGH N/A
- ALXO $1.88
- Average True Range (ATR)
- YYGH 0.00
- ALXO 0.19
- MACD
- YYGH 0.00
- ALXO 0.02
- Stochastic Oscillator
- YYGH 0.00
- ALXO 81.15
About YYGH YY GROUP HOLDING LIMITED
YY Group Holding Ltd is a data and technology driven company focused on developing enterprise intelligent labor matching services and smart cleaning services founded in Singapore. It provides enterprise manpower outsourcing and smart cleaning services in Singapore and Malaysia. The group has two operating segment, which is cleaning services segment and manpower outsourcing services, Maximum revenue is generated from cleaning services.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.